Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800
Debt
Debt-to-Equity Ratio0.22
Current Ratio7.20
Quick Ratio7.20
Price-To-Earnings
Trailing P/E Ratio-12.82
Forward P/E Ratio-12.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.11 million
Price / Sales168.23
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book8.66
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-42,950,000.00
Net Margins-1,143.99%
Return on Equity-77.27%
Return on Assets-54.40%
Miscellaneous
Employees80
Outstanding Shares52,860,000
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.05. The biopharmaceutical company earned $1 million during the quarter, compared to the consensus estimate of $1.82 million. Fate Therapeutics had a negative net margin of 1,143.99% and a negative return on equity of 77.27%. Fate Therapeutics's quarterly revenue was up .0% on a year-over-year basis. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
8 brokerages have issued 12-month price targets for Fate Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Fate Therapeutics' stock price to reach $16.1667 in the next year. View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (5/15/2018)
- 2. HC Wainwright analysts commented, "Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral Updated ProTmune data shows continued safety and efficacy. Yesterday, Fate Therapeutics announced additional Phase 1 clinical data from PROTECT. As a reminder, Fate is investigating ProTmune, a next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Data reported at ASH indicated that all subjects (n=7) remained relapse-free, and there were no events of graft failure or serious adverse events (SAEs) that were deemed related to ProTmune. In the study, three out of seven subjects experienced acute GvHD in the first 100 days. However, all subjects responded to standard-of care steroid treatment, and all three cases of GvHD resolved within 5-8 days." (3/20/2018)
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include Aerie Pharmaceuticals (AERI), Repligen (RGEN), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI), Solid Biosciences (SLDB), Audentes Therapeutics (BOLD), Acorda Therapeutics (ACOR), Cellectis (CLLS), Iovance Biotherapeutics (IOVA) and DBV Technologies (DBVT).
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 48)
- Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 50)
- Dr. Chris M. Storgard, Chief Medical Officer (Age 52)
- Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 45)
- Dr. Stewart Abbot, Chief Devel. Officer (Age 51)
Has Fate Therapeutics been receiving favorable news coverage?
Press coverage about FATE stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fate Therapeutics earned a coverage optimism score of 0.06 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Fate Therapeutics' major shareholders?
Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (12.59%), Franklin Resources Inc. (11.06%), BlackRock Inc. (5.49%), Artal Group S.A. (1.61%), Victory Capital Management Inc. (1.09%) and Northern Trust Corp (0.94%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.
Which major investors are selling Fate Therapeutics stock?
FATE stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Franklin Resources Inc., Neuberger Berman Group LLC and Hochman Cole Investment Advisors Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.
Which major investors are buying Fate Therapeutics stock?
FATE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Artal Group S.A., JPMorgan Chase & Co., Victory Capital Management Inc., Columbus Circle Investors, Northern Trust Corp and EAM Global Investors LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $13.08.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $650.69 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
